In the last trading session, 2.76 million Arcutis Biotherapeutics Inc (NASDAQ:ARQT) shares changed hands as the company’s beta touched 1.50. With the company’s per share price at $12.20 changed hands at -$0.19 or -1.53% during last session, the market valuation stood at $1.43B. ARQT’s last price was a discount, traded about -32.79% off its 52-week high of $16.20. The share price had its 52-week low at $6.99, which suggests the last value was 42.7% up since then.
Analysts gave the Arcutis Biotherapeutics Inc (ARQT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 1 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ARQT as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Arcutis Biotherapeutics Inc’s EPS for the current quarter is expected to be -0.28.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information
Instantly ARQT was in red as seen at the end of in last trading. With action -2.48%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -12.42%, with the 5-day performance at -2.48% in the red. However, in the 30-day time frame, Arcutis Biotherapeutics Inc (NASDAQ:ARQT) is -11.91% down.
The consensus price target for the stock as assigned by Wall Street analysts is 19, meaning bulls need an upside of 35.79% from its current market value. According to analyst projections, ARQT’s forecast low is 19 with 19 as the target high. To hit the forecast high, the stock’s price needs a -55.74% plunge from its current level, while the stock would need to soar -55.74% for it to hit the projected low.
Arcutis Biotherapeutics Inc (ARQT) estimates and forecasts
Year-over-year growth is forecast to reach 46.86% up from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 63.19M. 4 analysts are of the opinion that Arcutis Biotherapeutics Inc’s revenue for the current quarter will be 69.18M. The company’s revenue for the corresponding quarters a year ago was 49.57M and 30.86M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 27.48%. The estimates for the next quarter sales put growth at 124.18%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -48.07%. The 2025 estimates are for Arcutis Biotherapeutics Inc earnings to increase by 32.02%.
ARQT Dividends
Arcutis Biotherapeutics Inc is expected to release its next quarterly earnings report in March.
SUVRETTA CAPITAL MANAGEMENT, LLC holds the second largest percentage of outstanding shares, with 8.1021% or 10.0 million shares worth $93.04 million as of 2024-06-30.
